A single-center, randomized, double-blind, placebo-controlled, dose-escalation clinical study of the safety, tolerability, and pharmacokinetic/pharmacodynamic properties of single and multiple injections of RAB001 in healthy subjects.
Latest Information Update: 20 Mar 2026
At a glance
- Drugs RAB 001 (Primary)
- Indications Osteonecrosis
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 20 Mar 2026 New trial record